Headline Event - Transcept hoping for a dream approval
Source EP Vantage
Company Transcept Pharmaceuticals, Alexza Pharmaceuticals, Orexo, Purdue Pharma, Somaxon Pharmaceuticals 
Date October 22, 2009
 

With the PDUFA date for its lead product on October 30, hopefully Transcept Pharmaceuticals’ management team will not be experiencing too many wakeful nights over the prospects for the approval for their sleep disorder drug, Intermezzo.

Unlike the majority of sleep aids currently on the market, which focus on trying to get insomniacs to sleep, Intermezzo targets people who have no trouble falling asleep, but suffer from nocturnal waking. At present there are no approved products for this specialist indication, making it a very attractive niche opportunity. Zacks investment research has placed a $500m peak sale value on the drug and estimates royalties to Transcept of $97m by 2014.
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd